Top Markets
Coin of the day
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Peringkat dalam Saham #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Harga Saham
$0.00001
Terakhir disinkronkan: 2026-09-10
Kapitalisasi Pasar
$50.01K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan MultiCell Technologies, Inc. (MCET)

Kategori

Rasio P/S untuk MultiCell Technologies, Inc. (MCET)
Rasio P/S per September 2026 TTM: 1.01K
Menurut laporan keuangan dan harga saham terbaru dari MultiCell Technologies, Inc., rasio P/S saat ini (TTM) adalah 1.01K. Pada akhir 2013, rasio P/S perusahaan adalah 27.21.
Riwayat rasio P/S untuk MultiCell Technologies, Inc. dari 2013 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
2026 (TTM) 1.01K 3,255.43%
2014 30.22 11.07%
2013 27.21 0.00%
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
10.95 -98.92%
US
12.19 -98.80%
NL
24.99 -97.54%
US
3.75 -99.63%
AU
- -
CH